Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies

Figure 2 Kaplan-Meier curve showing overall survival. A: The entire cohort of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases treated under uncommon indications. The median overall survival was 28 months. Shaded areas represent 95% confidence intervals; B: Stratified by tumor origin in patients treated with CRS and HIPEC for peritoneal metastases under uncommon indications. Only patients with ≥ 6 months of follow-up were included; C: Stratified by tumor group: Breast cancer, uterine cancer, and all other uncommon indications. Patients with breast cancer showed the most favorable survival, followed by those with uterine cancer, while patients with other tumor types experienced the poorest outcomes. HCC: Hepatocellular carcinoma; FU: Follow-up.